Cover
Cover - $ / shares | 6 Months Ended | |
Jun. 30, 2024 | Aug. 19, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2024 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2024 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-54554 | |
Entity Registrant Name | Therapeutic Solutions International, Inc. | |
Entity Central Index Key | 0001419051 | |
Entity Tax Identification Number | 45-1226465 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 701 Wild Rose Lane | |
Entity Address, City or Town | Elk City | |
Entity Address, State or Province | ID | |
Entity Address, Postal Zip Code | 83525 | |
City Area Code | (760) | |
Local Phone Number | 295-7208 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 4,884,095,275 | |
Entity Listing, Par Value Per Share | $ 0.001 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 8,318 | $ 27,823 |
Accounts receivable | 17,289 | 19,196 |
Inventory | 17,806 | 22,574 |
Prepaid expenses and other current assets | 692,857 | 16,320 |
Total current assets | 736,270 | 85,913 |
Property and equipment, net | 368,915 | 374,355 |
Right-of-use asset | 111,848 | 125,557 |
Other assets | 2,558,091 | 2,706,187 |
Total assets | 3,775,124 | 3,292,012 |
Current liabilities: | ||
Accrued expenses and other current liabilities | 553,689 | 536,118 |
Lease liability | 25,917 | 20,525 |
Convertible notes payable, net of discount of $48,554 and $112,384 at June 30, 2024 and December 31, 2023, respectively | 127,246 | 49,616 |
Derivative liabilities | 47,220 | 181,070 |
Total current liabilities | 1,850,175 | 1,899,586 |
LONG TERM LIABILITIES | ||
Notes payable, net of current portion | 3,215 | 5,512 |
Lease liability, net of current portion | 85,931 | 105,032 |
TOTAL LIABILITIES | 1,939,321 | 2,010,130 |
Commitments and contingencies | ||
Shareholders’ Equity: | ||
Common stock, $0.001 par value; 6,500,000,000 and 5,500,000,000 shares authorized, respectively; 4,659,017,624 and 3,802,666,978 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 4,659,019 | 3,802,668 |
Additional paid-in capital | 17,977,536 | 17,670,092 |
Subscription receivable | (21,000) | (21,000) |
Accumulated deficit | (21,301,652) | (20,326,465) |
Total shareholders’ equity | 1,313,904 | 1,125,295 |
Non-controlling interest | 521,899 | 156,587 |
Total shareholders’ equity - Therapeutic Solutions International, Inc. | 1,835,803 | 1,281,882 |
Total liabilities and shareholders’ equity | 3,775,124 | 3,292,012 |
Series A Preferred Stock [Member] | ||
Shareholders’ Equity: | ||
Preferred stock, value | ||
Series B Preferred Stock [Member] | ||
Shareholders’ Equity: | ||
Preferred stock, value | 1 | |
Nonrelated Party [Member] | ||
Current liabilities: | ||
Accounts payable | 366,222 | 397,674 |
Notes payable | 4,638 | 4,638 |
Related Party [Member] | ||
Current liabilities: | ||
Accounts payable | 10,685 | 7,204 |
Notes payable | $ 714,558 | $ 702,741 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Convertible notes payable, discount amount | $ 48,554 | $ 112,384 |
Preferred stock, shares issued | 1,002 | |
Preferred stock, shares outstanding | 1,002 | |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 6,500,000,000 | 5,500,000,000 |
Common stock, shares issued | 4,659,017,624 | 3,802,666,978 |
Common stock, shares outstanding | 4,659,017,624 | 3,802,666,978 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 2 | 2 |
Preferred stock, shares outstanding | 2 | 2 |
Series B Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 1,000 | 0 |
Preferred stock, shares outstanding | 1,000 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Income Statement [Abstract] | ||||
Net sales | $ 20,005 | $ 26,308 | $ 41,819 | $ 49,431 |
Cost of goods sold | 6,727 | 10,699 | 14,217 | 19,165 |
Gross profit | 13,278 | 15,609 | 27,602 | 30,266 |
Operating expenses: | ||||
General and administrative | 100,676 | 113,343 | 211,549 | 232,744 |
Salaries, wages, and related costs | 104,175 | 113,954 | 214,532 | 224,479 |
Consulting fees | 7,322 | 53,473 | 267,462 | 122,757 |
Legal and professional fees | 187,573 | 68,805 | 335,156 | 161,392 |
Research and development | 17,570 | 208,540 | 76,182 | 261,267 |
Total operating expenses | 417,316 | 558,115 | 1,104,881 | 1,002,639 |
Loss from operations | (404,038) | (542,506) | (1,077,279) | (972,373) |
Other income (expense): | ||||
Gain (loss) on derivative liabilities | 20,415 | 6,141 | (13,826) | 24,275 |
Change in fair value of derivative liabilities | (5,921) | 10,624 | 26,483 | (33,712) |
Interest expense | (74,013) | (122,261) | (163,203) | (244,073) |
Gain on extinguishment of debt | 85,546 | 85,546 | ||
Total other income (expense) | (59,519) | (19,950) | (150,546) | (167,964) |
Loss before provision for income taxes | (463,557) | (562,456) | (1,227,825) | (1,140,337) |
Provision for income taxes | 800 | 800 | 800 | 800 |
Net loss before non-controlling interest | (464,357) | (563,256) | (1,228,625) | (1,141,137) |
Loss attributable to non-controlling interest | (74,311) | (856) | (253,438) | (856) |
Net loss attributable to Therapeutic Solutions International, Inc. | $ (390,046) | $ (562,400) | $ (975,187) | $ (1,140,281) |
Net loss per share - basic | $ 0 | $ 0 | $ 0 | $ 0 |
Net loss per share - diluted | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average shares outstanding - basic | 4,511,799,474 | 2,976,127,083 | 4,232,658,617 | 2,834,408,024 |
Weighted average shares outstanding - diluted | 4,511,799,474 | 2,976,127,083 | 4,232,658,617 | 2,834,408,024 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($) | Preferred Stock [Member] Series A Preferred Stock [Member] | Preferred Stock [Member] Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Shares to be Issued [Member] | Receivables from Stockholder [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Total |
Balance at Dec. 31, 2022 | $ 2,617,392 | $ 16,655,643 | $ 126,324 | $ (21,000) | $ (18,156,651) | $ 163,473 | $ 1,385,181 | ||
Balance, shares at Dec. 31, 2022 | 2 | 2,617,390,830 | |||||||
Common stock issued for services | $ 46,000 | 135,600 | (102,000) | 79,600 | |||||
Common stock issued for services, shares | 46,000,000 | ||||||||
Common stock issued for salaries | $ 4,082 | 15,918 | 20,000 | ||||||
Common stock issued for salaries, shares | 4,081,632 | ||||||||
Common stock issued for cash | $ 270,091 | 218,261 | 488,352 | ||||||
Common stock issued for cash, shares | 270,091,435 | ||||||||
Common stock issued by subsidiary for services | 1,831 | 1,831 | |||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 196,480 | 476,239 | (15,000) | 657,719 | |||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares | 196,480,177 | ||||||||
Net loss | (1,140,281) | (856) | (1,141,137) | ||||||
Balance at Jun. 30, 2023 | $ 3,134,045 | 17,503,492 | 9,324 | (21,000) | (19,296,932) | 162,617 | 1,491,546 | ||
Balance, shares at Jun. 30, 2023 | 2 | 3,134,044,074 | |||||||
Balance at Dec. 31, 2022 | $ 2,617,392 | 16,655,643 | 126,324 | (21,000) | (18,156,651) | 163,473 | 1,385,181 | ||
Balance, shares at Dec. 31, 2022 | 2 | 2,617,390,830 | |||||||
Common stock issued for salaries | $ 110,000 | ||||||||
Common stock issued for salaries, shares | 64,081,632 | ||||||||
Balance at Dec. 31, 2023 | $ 3,802,668 | 17,670,092 | (21,000) | (20,326,465) | 156,587 | 1,281,882 | |||
Balance, shares at Dec. 31, 2023 | 2 | 3,802,666,978 | |||||||
Balance at Mar. 31, 2023 | $ 2,748,958 | 16,999,222 | 9,324 | (21,000) | (18,734,532) | 163,473 | 1,165,445 | ||
Balance, shares at Mar. 31, 2023 | 2 | 2,748,956,631 | |||||||
Common stock issued for services | $ 25,000 | 35,000 | 60,000 | ||||||
Common stock issued for services, shares | 25,000,000 | ||||||||
Common stock issued for salaries | |||||||||
Common stock issued for cash | $ 209,866 | 148,400 | 358,266 | ||||||
Common stock issued for cash, shares | 209,866,610 | ||||||||
Common stock issued by subsidiary for services | 1,831 | 1,831 | |||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 150,221 | 319,039 | 469,260 | ||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares | 150,220,833 | ||||||||
Net loss | (562,400) | (856) | (563,256) | ||||||
Common stock issued for prepaid fees | |||||||||
Relief of derivative liabilities | |||||||||
Common stock issued | |||||||||
Beneficial conversion feature on note payable | |||||||||
Balance at Jun. 30, 2023 | $ 3,134,045 | 17,503,492 | 9,324 | (21,000) | (19,296,932) | 162,617 | 1,491,546 | ||
Balance, shares at Jun. 30, 2023 | 2 | 3,134,044,074 | |||||||
Balance at Dec. 31, 2023 | $ 3,802,668 | 17,670,092 | (21,000) | (20,326,465) | 156,587 | 1,281,882 | |||
Balance, shares at Dec. 31, 2023 | 2 | 3,802,666,978 | |||||||
Common stock issued for services | $ 76,000 | (11,600) | 64,400 | ||||||
Common stock issued for services, shares | 76,000,000 | ||||||||
Common stock issued for salaries | $ 80,357 | (20,357) | $ 60,000 | ||||||
Common stock issued for salaries, shares | 80,357,142 | 80,357,142 | |||||||
Common stock issued for cash | $ 303,157 | (119,304) | $ 183,853 | ||||||
Common stock issued for cash, shares | 303,156,710 | ||||||||
Common stock issued by subsidiary for services | 506,250 | 618,750 | 1,125,000 | ||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 376,837 | (57,544) | 319,293 | ||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares | 376,836,794 | ||||||||
Net loss | (975,187) | (253,438) | (1,228,625) | ||||||
Common stock issued for prepaid fees | $ 20,000 | $ 20,000 | |||||||
Common stock issued for prepaid fees, shares | 20,000,000 | 20,000,000 | |||||||
Preferred stock issued for cash | $ 1 | 9,999 | $ 10,000 | ||||||
Preferred stock issued for cash, shares | 1,000 | ||||||||
Balance at Jun. 30, 2024 | $ 1 | $ 4,659,019 | 17,977,536 | (21,000) | (21,301,652) | 521,899 | 1,835,803 | ||
Balance, shares at Jun. 30, 2024 | 2 | 1,000 | 4,659,017,624 | ||||||
Balance at Mar. 31, 2024 | $ 1 | $ 4,230,118 | 18,111,652 | (21,000) | (20,911,606) | 596,210 | 2,005,375 | ||
Balance, shares at Mar. 31, 2024 | 2 | 1,000 | 4,230,116,869 | ||||||
Common stock issued for services | $ 25,000 | (6,500) | 18,500 | ||||||
Common stock issued for services, shares | 25,000,000 | ||||||||
Common stock issued for salaries | $ 80,357 | (20,357) | 60,000 | ||||||
Common stock issued for salaries, shares | 80,357,142 | ||||||||
Common stock issued for cash | $ 71,587 | (36,825) | 34,762 | ||||||
Common stock issued for cash, shares | 71,586,542 | ||||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 251,957 | (70,434) | 181,523 | ||||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares | 251,957,071 | ||||||||
Net loss | (390,046) | (74,311) | (464,357) | ||||||
Balance at Jun. 30, 2024 | $ 1 | $ 4,659,019 | $ 17,977,536 | $ (21,000) | $ (21,301,652) | $ 521,899 | $ 1,835,803 | ||
Balance, shares at Jun. 30, 2024 | 2 | 1,000 | 4,659,017,624 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Cash flows from operating activities | ||
Net loss | $ (1,228,625) | $ (1,141,137) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation to consultants | 1,146,600 | |
Stock-based compensation to related parties | 42,800 | 79,600 |
Loss on derivative liabilities | 13,826 | (24,275) |
Change in fair value of derivative liabilities | (26,483) | 33,712 |
Gain on extinguishment of debt | (85,546) | |
Amortization of prepaid stock-based compensation | 14,204 | 101,162 |
Amortization of debt discount | 139,630 | 221,686 |
Patent amortization | 148,387 | 148,387 |
Depreciation | 5,441 | 5,441 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 1,907 | 7,819 |
Inventory | 4,768 | 11,036 |
Prepaid expenses and other current assets | (671,032) | 70,528 |
Right-of-use asset | 13,709 | 16,654 |
Accounts payable | (31,453) | (46,615) |
Accounts payable - related parties | 3,481 | (6) |
Accrued expenses and other current liabilities | 87,627 | 80,026 |
Lease liability | (13,709) | (16,654) |
Net cash used in operating activities | (348,922) | (538,182) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Issuance of note receivable | (800) | |
Net cash used by investing activities | (800) | |
Cash flows from financing activities | ||
Payments on notes payable to related party | (9) | (12) |
Proceeds from notes payable to related party | 7,869 | 3,360 |
Proceeds from convertible notes payable | 130,000 | 143,750 |
Payments on notes payable | (2,296) | (2,428) |
Proceeds from sale of preferred stock | 10,000 | |
Proceeds from sale of common stock | 183,853 | 488,352 |
Net cash provided by financing activities | 329,417 | 633,022 |
Net increase (decrease) in cash, cash equivalents and restricted cash | (19,505) | 94,040 |
Cash and cash equivalents at beginning of period | 27,823 | 29,043 |
Cash and cash equivalents at end of period | 8,318 | 123,083 |
Supplemental cash flow information: | ||
Cash paid for interest | 1,132 | 2,091 |
Cash paid for income taxes | 800 | 800 |
Non-cash investing and financing transactions: | ||
Original issuance discount on convertible notes payable | 45,800 | 17,500 |
Debt discount recorded in connection with derivative liability | 30,000 | 142,565 |
Common stock issued in conversion of convertible notes payable and interest | 319,293 | 657,719 |
Common stock issued for prepaid fees | 20,000 | 1,831 |
Common stock issued for accrued salaries | 60,000 | 20,000 |
Accrued interest added to principal | 3,956 | 9,170 |
Right of use asset and lease liability | $ 146,244 |
Organization and Business Descr
Organization and Business Description | 6 Months Ended |
Jun. 30, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business Description | Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSOI” or the “Company”) was organized August 6, 2007 Business Description Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health. Nutraceutical Division Regenerative Medicine The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal like stromal cells. Immunotherapies TSOI has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson’s disease developed on our StemVacs platform. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 Going Concern Management does not expect existing cash as of June 30, 2024, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2024, the Company has incurred losses totaling $ 21.3 |
Basis of presentation and signi
Basis of presentation and significant accounting policies | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Basis of presentation and significant accounting policies | Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. These financial statements should be read in conjunction with the annual audited financial statements. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries, its 68 44.56 Accounts Receivable On January 1, 2023, the Company adopted ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASC 326). This standard replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. The company looks at historical losses, assesses current and future events to adjust historical information as necessary, and applies percentages to accounts receivable balances based on aging. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 The company recorded an allowance for doubtful accounts of $ 10,647 6,807 Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. The sales were $ 41,819 49,431 Returns. Our estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s revenues in the accompanying financial statements. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price. Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after an initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2024 and 2023, as disclosed in Note 7 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 47,220 181,070 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2024 and December 31, 2023, the Company has level 3 fair value calculations on derivative liabilities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 The following is the change in derivative liability for the six months ended June 30, 2024: Schedule of Change in Derivative Liability Balance, December 31, 2023 $ 181,070 Issuance of new derivative liabilities 85,264 Conversions (192,631 ) Change in fair market value of derivative liabilities (26,483 ) Balance, June 30, 2024 $ 47,220 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Non-Controlling Interests Non-controlling interests disclosed within the consolidated statement of operations represent the minority ownership’s 68 44.56 Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of June 30, 2024, and 2023 a total of 1,605,641,025 586,973,744 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 Depreciation and Amortization Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2024, and 2023 were $ 5,441 5,441 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2024, and 2023 was $ 148,387 148,387 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within the general administrative expenses. Advertising Advertising costs are expensed as incurred. Advertising expense for the six months ended June 30, 2024 and 2023 were $ 696 1,084 Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 76,182 261,267 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to non-employees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is the fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 111,848 Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The accounting guidance has been adopted with no significant financial statement impact. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 |
Prepaid expense and other curre
Prepaid expense and other current assets | 6 Months Ended |
Jun. 30, 2024 | |
Prepaid Expense And Other Current Assets | |
Prepaid expense and other current assets | Note 3 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2024 December 31, 2023 Prepaid consulting $ 15,083 $ 11,037 Insurance 613 1,167 Prepaid costs and other 677,161 4,116 Total $ 692,857 $ 16,320 |
Fixed assets
Fixed assets | 6 Months Ended |
Jun. 30, 2024 | |
Property, Plant and Equipment [Abstract] | |
Fixed assets | Note 4 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets June 30, 2024 December 31, 2023 Land $ 347,381 $ 347,381 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 413,517 413,517 Accumulated depreciation (44,602 ) (39,162 ) Property and equipment, net $ 368,915 $ 374,355 Depreciation expenses were $ 5,441 5,441 |
Other assets
Other assets | 6 Months Ended |
Jun. 30, 2024 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Other assets | Note 5 – Other assets Schedule of other assets June 30, 2024 December 31, 2023 License, net $ 2,553,676 $ 2,702,064 Prepaid consulting 292 - Deposit 4,123 4,123 Licenses, net $ 2,558,091 $ 2,706,187 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses June 30, 2024 December 31, 2023 License $ 3,261,122 $ 3,261,122 Accumulated amortization (707,446 ) (559,058 ) Licenses, net $ 2,553,676 $ 2,702,064 Amortization expense for the six months ended June 30, 2024, and 2023 was $ 148,387 148,387 |
Notes Payable-Related Party
Notes Payable-Related Party | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Notes Payable-Related Party | Note 6 - Notes Payable-Related Party Notes payable-related parties consist of: Schedule of Notes Payable Related Parties June 30, 2024 December 31, 2023 Various notes payable – Board of Directors Member, unsecured, including interest at 10 January 2024 to November 2024 $ 14,379 $ 6,510 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 31,360 30,604 One note payable – Chief Executive Officer, unsecured, no 534,419 534,427 Note payable – unsecured, including interest at 8 December 31, 2019 134,400 131,200 $ 714,558 $ 702,741 At June 30, 2024 and 2023, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 714,558 692,284 4,554 1,978 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 |
Convertible Notes Payable
Convertible Notes Payable | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Convertible Notes Payable | Note 7 – Convertible Notes Payable At various times during the six months ended June 30, 2024, the Company entered into convertible promissory notes with principal amounts totaling $ 175,800 130,000 45,800 140,800 15 These notes are only convertible following a default event at a conversion price equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The remaining convertible promissory notes incur interest at 10% per annum and mature on dates ranging from November 2024 to January 2025. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% 1,605,641,025 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the six months ended June 30, 2024, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 85,264 55,264 0.006 0.0018 0 164 4.82 one year During the six months ended June 30, 2024, convertible notes with principal and accrued interest balances totaling $ 168,100 376,836,794 41,437 0.0003 0.0007 0.0006 0.0013 0 106 160 4.83 5.21 0.43 0.49 On June 30, 2024, the derivative liabilities on the remaining convertible notes were revalued at $ 47,220 26,483 0.0005 0.001 0 184 5.09 0.53 The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the six months ended June 30, 2024 and 2023, the Company amortized $ 139,630 221,686 48,554 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 |
Equity
Equity | 6 Months Ended |
Jun. 30, 2024 | |
Equity [Abstract] | |
Equity | Note 8 – Equity Our authorized capital stock consists of an aggregate of 5,505,000,000 5,500,000,000 0.001 5,000,000 4,659,017,624 1,002 Our non-controlling interest’s authorized capital stock consists of an aggregate of 505,000,000 500,000,000 0.0001 5,000,000 18,408,333 0 6,953 68 Our non-controlling interest’s authorized capital stock consists of an aggregate of 505,000,000 500,000,000 0.0001 5,000,000 35,145,000 0 528,852 45 In 2023, we issued 556,632,297 790,432 In 2023, we issued 115,257,394 176,911 In 2023, we issued 64,081,632 110,000 In 2023, we issued 389,304,825 657,719 In 2023, we issued 60,000,000 96,000 In 2024, we issued 303,156,710 183,853 In 2024, we issued 76,000,000 64,400 In 2024, we issued 80,357,142 60,000 In 2024, we issued 376,836,794 shares of common stock for the conversion of convertible notes of $ 319,293 In 2024, we issued 20,000,000 20,000 On February 9, 2024, the Board of Directors designated “Series B Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada. The series of preferred stock shall be designated as Series B 5% Convertible Preferred Stock (“Series B Preferred Stock”) and the number of shares so designated shall be up to 1,000,000 0.001 10.00 5 th 10 100 20 In 2024, we issued 1,000 10,000 During the year ended December 31, 2023, the Company’s subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third parties which represented 32 2,989 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 During the six months ended June 30, 2024, the Company’s subsidiary, Campbell Neurosciences, Inc., issued shares of its common stock to third parties which represented 44.56 250,449 |
Legal proceedings
Legal proceedings | 6 Months Ended |
Jun. 30, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal proceedings | Note 9 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations. TSOI vs Does 1-50 Case No.: 37-2023-00045520-CU-DF-NC; Case filed: 10/19/2023; First Amended Complaint filed: 1/22/2024. TSOI has filed suit to bring action against anonymous online posters of defamatory accusations against TSOI and its officer and directors. It is a Complaint for damages and injunctive relief and includes Commercial Disparagement/Trade Libel, Civil Conspiracy to Defame, violation of CA Bus. Code §17200, and Intentional Interference with Perspective Economic Advantage. This matter is being managed by outside counsel, Matthew R. Miller of Miller Law Firm. Shepard vs Veltmeyer, et al. Case No.: 37-2023-00043103 CU-BTCTL; Complaint Filed: October 4, 2023. Kyle Shepard sued the Veltmeyer Institute for Advanced Biologics, LLC (“Veltmeyer Institute”), Dr. James Veltmeyer, Managing Member, TSOI and Dr. Thomas Ichim for, fraud (Veltmeyer only), breach of fiduciary duty (Veltmeyer only), conversion (Veltmeyer), accounting action and constructive trust (all defendants), and intentional interference with contracts (Veltmeyer, Ichim and TSOI). This matter is being managed by outside counsel, Matthew R. Miller of Miller Law Firm. The total amount demanded is $ 1,745,366.27 |
Subsequent events
Subsequent events | 6 Months Ended |
Jun. 30, 2024 | |
Subsequent Events [Abstract] | |
Subsequent events | Note 10 – Subsequent events On July 1, 2024, we issued 2,000,000 0.0008 On July 8, 2024, we issued 76,562,500 35,000 On July 9, 2024, we issued 25,000,000 0.0008 On July 9, 2024, we issued 10,000,000 0.0008 On July 12, 2024, we issued 33,333,333 0.0006 On July 12, 2024, we issued 10,000,000 0.0006 On August 13, we issued 68,181,818 30,000 In accordance with ASC 855, the Company has analyzed its operations through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 11 – Commitments and Contingencies Effective March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 60 April 30, 2028 12,846 12,604 The lease will expire in 2028. The weighted average discount rate used for this lease is 1.1 |
Basis of presentation and sig_2
Basis of presentation and significant accounting policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. These financial statements should be read in conjunction with the annual audited financial statements. |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries, its 68 44.56 |
Accounts Receivable | Accounts Receivable On January 1, 2023, the Company adopted ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASC 326). This standard replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. The company looks at historical losses, assesses current and future events to adjust historical information as necessary, and applies percentages to accounts receivable balances based on aging. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 The company recorded an allowance for doubtful accounts of $ 10,647 6,807 |
Revenue Recognition | Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. The sales were $ 41,819 49,431 Returns. Our estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s revenues in the accompanying financial statements. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price. Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after an initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 |
Inventories | Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. |
Derivative Liabilities | Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2024 and 2023, as disclosed in Note 7 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 47,220 181,070 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2024 and December 31, 2023, the Company has level 3 fair value calculations on derivative liabilities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 The following is the change in derivative liability for the six months ended June 30, 2024: Schedule of Change in Derivative Liability Balance, December 31, 2023 $ 181,070 Issuance of new derivative liabilities 85,264 Conversions (192,631 ) Change in fair market value of derivative liabilities (26,483 ) Balance, June 30, 2024 $ 47,220 |
Use of Estimates | Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. |
Non-Controlling Interests | Non-Controlling Interests Non-controlling interests disclosed within the consolidated statement of operations represent the minority ownership’s 68 44.56 |
Net Loss Per Share | Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of June 30, 2024, and 2023 a total of 1,605,641,025 586,973,744 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 |
Depreciation and Amortization | Depreciation and Amortization Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2024, and 2023 were $ 5,441 5,441 |
Intangible Assets | Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2024, and 2023 was $ 148,387 148,387 |
Long-lived Assets | Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. |
Shipping and Handling | Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within the general administrative expenses. |
Advertising | Advertising Advertising costs are expensed as incurred. Advertising expense for the six months ended June 30, 2024 and 2023 were $ 696 1,084 |
Research and Development | Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 76,182 261,267 |
Income Taxes | Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 |
Stock-Based Compensation | Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to non-employees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is the fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. |
Leases | Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 111,848 |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The accounting guidance has been adopted with no significant financial statement impact. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures. |
Basis of presentation and sig_3
Basis of presentation and significant accounting policies (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Schedule of Change in Derivative Liability | The following is the change in derivative liability for the six months ended June 30, 2024: Schedule of Change in Derivative Liability Balance, December 31, 2023 $ 181,070 Issuance of new derivative liabilities 85,264 Conversions (192,631 ) Change in fair market value of derivative liabilities (26,483 ) Balance, June 30, 2024 $ 47,220 |
Prepaid expense and other cur_2
Prepaid expense and other current assets (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Prepaid Expense And Other Current Assets | |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2024 December 31, 2023 Prepaid consulting $ 15,083 $ 11,037 Insurance 613 1,167 Prepaid costs and other 677,161 4,116 Total $ 692,857 $ 16,320 |
Fixed assets (Tables)
Fixed assets (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Fixed Assets | Fixed assets consist of the following: Schedule of Fixed Assets June 30, 2024 December 31, 2023 Land $ 347,381 $ 347,381 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 413,517 413,517 Accumulated depreciation (44,602 ) (39,162 ) Property and equipment, net $ 368,915 $ 374,355 |
Other assets (Tables)
Other assets (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of other assets | Schedule of other assets June 30, 2024 December 31, 2023 License, net $ 2,553,676 $ 2,702,064 Prepaid consulting 292 - Deposit 4,123 4,123 Licenses, net $ 2,558,091 $ 2,706,187 |
Schedule of Net Licenses | Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses June 30, 2024 December 31, 2023 License $ 3,261,122 $ 3,261,122 Accumulated amortization (707,446 ) (559,058 ) Licenses, net $ 2,553,676 $ 2,702,064 |
Notes Payable-Related Party (Ta
Notes Payable-Related Party (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable Related Parties | Notes payable-related parties consist of: Schedule of Notes Payable Related Parties June 30, 2024 December 31, 2023 Various notes payable – Board of Directors Member, unsecured, including interest at 10 January 2024 to November 2024 $ 14,379 $ 6,510 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 31,360 30,604 One note payable – Chief Executive Officer, unsecured, no 534,419 534,427 Note payable – unsecured, including interest at 8 December 31, 2019 134,400 131,200 $ 714,558 $ 702,741 |
Organization and Business Des_2
Organization and Business Description (Details Narrative) $ in Millions | 6 Months Ended |
Jun. 30, 2024 USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Entity incorporation date | Aug. 06, 2007 |
Losses for the period | $ 21.3 |
Schedule of Change in Derivativ
Schedule of Change in Derivative Liability (Details) | 6 Months Ended |
Jun. 30, 2024 USD ($) | |
Accounting Policies [Abstract] | |
Beginning Balance | $ 181,070 |
Issuance of new derivative liabilities | 85,264 |
Conversions | (192,631) |
Change in fair market value of derivative liabilities | (26,483) |
Ending Balance | $ 47,220 |
Basis of presentation and sig_4
Basis of presentation and significant accounting policies (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Allowance for doubtful accounts | $ 10,647 | $ 10,647 | $ 6,807 | ||
Sales | 20,005 | $ 26,308 | $ 41,819 | $ 49,431 | |
Payment description | Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price. Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after an initial $1,500,000 in aggregate purchases will be sold at 60% off retail | ||||
FDIC insured amount | 250,000 | $ 250,000 | |||
Cash, uninsured amount | 0 | 0 | 0 | ||
Derivative liabilities | 47,220 | $ 47,220 | $ 181,070 | ||
Antidilutive securities excluded from computation of earnings per share | 1,605,641,025 | 586,973,744 | |||
Depreciation expense | $ 5,441 | $ 5,441 | |||
Amortization expense of intangible assets | 148,387 | 148,387 | |||
Advertising expense | 696 | 1,084 | |||
Research and development expense | 17,570 | $ 208,540 | 76,182 | $ 261,267 | |
Lease liability | $ 111,848 | $ 111,848 | |||
Res Nova Bio Inc [Member] | |||||
Ownership percentage | 68% | 68% | |||
Non-Controlling interest percentage | 68% | 68% | |||
Campbell Neurosciences Inc [Member] | |||||
Ownership percentage | 44.56% | 44.56% | |||
Non-Controlling interest percentage | 44.56% | 44.56% |
Schedule of Prepaid Expenses an
Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Prepaid Expense And Other Current Assets | ||
Prepaid consulting | $ 15,083 | $ 11,037 |
Insurance | 613 | 1,167 |
Prepaid costs and other | 677,161 | 4,116 |
Total | $ 692,857 | $ 16,320 |
Schedule of Fixed Assets (Detai
Schedule of Fixed Assets (Details) - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Property, Plant and Equipment [Line Items] | ||
Total | $ 413,517 | $ 413,517 |
Accumulated depreciation | (44,602) | (39,162) |
Property and equipment, net | 368,915 | 374,355 |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 347,381 | 347,381 |
Vehicles [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 50,514 | 50,514 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 6,135 | 6,135 |
Office Furniture And Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 7,912 | 7,912 |
Shipping And Other Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 1,575 | $ 1,575 |
Fixed assets (Details Narrative
Fixed assets (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 5,441 | $ 5,441 |
Schedule of other assets (Detai
Schedule of other assets (Details) - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
License, net | $ 2,553,676 | $ 2,702,064 |
Prepaid consulting | 292 | |
Deposit | 4,123 | 4,123 |
Licenses, net | $ 2,558,091 | $ 2,706,187 |
Schedule of Net Licenses (Detai
Schedule of Net Licenses (Details) - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
License | $ 3,261,122 | $ 3,261,122 |
Accumulated amortization | (707,446) | (559,058) |
Licenses, net | $ 2,553,676 | $ 2,702,064 |
Other assets (Details Narrative
Other assets (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Amortization expenses | $ 148,387 | $ 148,387 |
Schedule of Notes Payable Relat
Schedule of Notes Payable Related Parties (Details) (Parenthetical) - Related Party [Member] | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | |
Notes Payable One [Member] | |||
Short-Term Debt [Line Items] | |||
Debt interest percentage | 10% | 10% | |
Debt instrument maturity date | January 2024 to November 2024 | January 2024 to November 2024 | |
Notes Payable Two [Member] | |||
Short-Term Debt [Line Items] | |||
Debt interest percentage | 8% | 10% | 10% |
Debt instrument maturity date | Dec. 31, 2019 | Dec. 31, 2019 | |
Notes Payable Three [Member] | |||
Short-Term Debt [Line Items] | |||
Debt interest percentage | 0% | 0% | |
Notes Payable Four [Member] | |||
Short-Term Debt [Line Items] | |||
Debt interest percentage | 8% | 8% | |
Debt instrument maturity date | Dec. 31, 2019 | Dec. 31, 2019 |
Schedule of Notes Payable Rel_2
Schedule of Notes Payable Related Parties (Details) - Related Party [Member] - USD ($) | Jun. 30, 2024 | Dec. 31, 2023 |
Short-Term Debt [Line Items] | ||
Notes payable to related party | $ 714,558 | $ 702,741 |
Notes Payable One [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable to related party | 14,379 | 6,510 |
Notes Payable Two [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable to related party | 31,360 | 30,604 |
Notes Payable Three [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable to related party | 534,419 | 534,427 |
Notes Payable Four [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable to related party | $ 134,400 | $ 131,200 |
Notes Payable-Related Party (De
Notes Payable-Related Party (Details Narrative) - Officers and Directors [Member] - USD ($) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Notes payable to related party | $ 714,558 | $ 692,284 |
Accrued interest | $ 4,554 | $ 1,978 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | |
Debt Instrument [Line Items] | |||||
Proceeds from convertible debt | $ 130,000 | $ 143,750 | |||
Derivative issuance liabilities | 85,264 | ||||
Gain loss on derivative liabilities | $ 20,415 | $ 6,141 | (13,826) | 24,275 | |
Derivative liabilities | 47,220 | 47,220 | $ 181,070 | ||
Amortization of interest expenses | 139,630 | 221,686 | |||
Convertible Promissory Note [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt discount | $ 48,554 | 48,554 | |||
Amortization of interest expenses | $ 139,630 | $ 221,686 | |||
Measurement Input, Conversion Price [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.006 | 0.006 | |||
Measurement Input, Share Price [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0018 | 0.0018 | |||
Measurement Input, Expected Dividend Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 0 | 0 | |||
Measurement Input, Price Volatility [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 164 | 164 | |||
Measurement Input, Risk Free Interest Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 4.82 | 4.82 | |||
Measurement Input, Expected Term [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input term | 1 year | ||||
Derivative [Member] | |||||
Debt Instrument [Line Items] | |||||
Gain loss on derivative liabilities | $ 55,264 | ||||
Convertible Promissory Note [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt principal amount | $ 175,800 | 175,800 | |||
Proceeds from convertible debt | 130,000 | ||||
Debt discount | 45,800 | 45,800 | |||
Principal amount | $ 140,800 | $ 140,800 | |||
Interest rate percentage | 15% | 15% | |||
Debt conversion description | These notes are only convertible following a default event at a conversion price equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The remaining convertible promissory notes incur interest at 10% per annum and mature on dates ranging from November 2024 to January 2025. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% | ||||
Common stock hares reserved for future issuance | shares | 1,605,641,025 | 1,605,641,025 | |||
Convertible Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Gain loss on derivative liabilities | $ 41,437 | ||||
Debt conversion | $ 168,100 | ||||
Debt conversion | shares | 376,836,794 | ||||
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0003 | 0.0003 | |||
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0007 | 0.0007 | |||
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Minimum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0006 | 0.0006 | |||
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Maximum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0013 | 0.0013 | |||
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 0 | 0 | |||
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 106 | 106 | |||
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 160 | 160 | |||
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 4.83 | 4.83 | |||
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 5.21 | 5.21 | |||
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input term | 5 months 4 days | ||||
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input term | 5 months 26 days | ||||
Remaining Convertible Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Gain loss on derivative liabilities | $ 26,483 | ||||
Derivative liabilities | $ 47,220 | $ 47,220 | |||
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.001 | 0.001 | |||
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 0 | 0 | |||
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 184 | 184 | |||
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | 5.09 | 5.09 | |||
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input term | 6 months 10 days | ||||
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member] | |||||
Debt Instrument [Line Items] | |||||
Derivative liability, measurement input | $ / shares | 0.0005 | 0.0005 |
Equity (Details Narrative)
Equity (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Feb. 09, 2024 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock, shares authorized | 6,500,000,000 | 6,500,000,000 | 5,500,000,000 | |||
Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||
Common stock, shares issued | 4,659,017,624 | 4,659,017,624 | 3,802,666,978 | |||
Common stock, shares outstanding | 4,659,017,624 | 4,659,017,624 | 3,802,666,978 | |||
Preferred stock, shares issued | 1,002 | 1,002 | ||||
Preferred stock, shares outstanding | 1,002 | 1,002 | ||||
Net loss attributable to the noncontrolling interest | $ 521,899 | $ 521,899 | $ 156,587 | |||
Common stock issued for investment in Private Placement | 34,762 | $ 358,266 | 183,853 | $ 488,352 | ||
Common stock issued for services | 18,500 | 60,000 | $ 64,400 | 79,600 | ||
Common stock issued for salaries, shares | 80,357,142 | |||||
Common stock issued for salaries | 60,000 | $ 60,000 | 20,000 | |||
Number of shares issued for convertible notes, value | 181,523 | 469,260 | $ 319,293 | 657,719 | ||
Common stock issued for Prepaid fees, shares | 20,000,000 | |||||
Common stock issued for Prepaid fees | $ 20,000 | |||||
Preferred stock, stated percentage | 100% | |||||
Tradings days | 20 days | |||||
Res Nova Bio Inc [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Net loss attributable to the noncontrolling interest | $ 2,989 | $ 2,989 | ||||
Non-Controlling interest percentage | 68% | 68% | ||||
Campbell Neurosciences Inc [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Net loss attributable to the noncontrolling interest | $ 250,449 | $ 250,449 | ||||
Non-Controlling interest percentage | 44.56% | 44.56% | ||||
Series B Preferred Stock [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Designated shares | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||
Preferred stock, shares issued | 1,000 | 1,000 | 0 | |||
Preferred stock, shares outstanding | 1,000 | 1,000 | 0 | |||
Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||
Preferred stock, stated value | $ 10 | |||||
Preferred stock, stated percentage | 5% | |||||
Land Improvements [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock issued for investment in Private Placement, shares | 60,000,000 | |||||
Common stock issued for investment in Private Placement | $ 96,000 | |||||
Convertible Notes Payable [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Number of shares issued for convertible notes | 376,836,794 | 389,304,825 | ||||
Number of shares issued for convertible notes, value | $ 319,293 | $ 657,719 | ||||
Consulting Services [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock issued for services, shares | 76,000,000 | 115,257,394 | ||||
Common stock issued for services | $ 64,400 | $ 176,911 | ||||
Private Placement [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock issued for investment in Private Placement, shares | 303,156,710 | 556,632,297 | ||||
Common stock issued for investment in Private Placement | $ 183,853 | $ 790,432 | ||||
Private Placement [Member] | Series B Preferred Stock [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock issued for investment in Private Placement, shares | 1,000 | |||||
Common stock issued for investment in Private Placement | $ 10,000 | |||||
Noncontrolling Interest [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock, shares issued | 35,145,000 | 35,145,000 | ||||
Common stock, shares outstanding | 35,145,000 | 35,145,000 | ||||
Common stock issued for investment in Private Placement | ||||||
Common stock issued for services | ||||||
Common stock issued for salaries | ||||||
Number of shares issued for convertible notes, value | ||||||
Common stock issued for Prepaid fees | ||||||
Common Stock [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Common stock issued for investment in Private Placement, shares | 71,586,542 | 209,866,610 | 303,156,710 | 270,091,435 | ||
Common stock issued for investment in Private Placement | $ 71,587 | $ 209,866 | $ 303,157 | $ 270,091 | ||
Common stock issued for services, shares | 25,000,000 | 25,000,000 | 76,000,000 | 46,000,000 | ||
Common stock issued for services | $ 25,000 | $ 25,000 | $ 76,000 | $ 46,000 | ||
Common stock issued for salaries, shares | 80,357,142 | 80,357,142 | 4,081,632 | 64,081,632 | ||
Common stock issued for salaries | $ 80,357 | $ 80,357 | $ 4,082 | $ 110,000 | ||
Number of shares issued for convertible notes | 251,957,071 | 150,220,833 | 376,836,794 | 196,480,177 | ||
Number of shares issued for convertible notes, value | $ 251,957 | $ 150,221 | $ 376,837 | $ 196,480 | ||
Common stock issued for Prepaid fees, shares | 20,000,000 | |||||
Common stock issued for Prepaid fees | $ 20,000 | |||||
Share price | $ 10 | |||||
Common Stock [Member] | Res Nova Bio Inc [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Non-Controlling interest percentage | 32% | 32% | ||||
Board of Directors Chairman [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Authorized capital stock | 5,505,000,000 | 5,505,000,000 | ||||
Common stock, shares authorized | 5,500,000,000 | 5,500,000,000 | ||||
Common stock, par value | $ 0.001 | $ 0.001 | ||||
Designated shares | 5,000,000 | 5,000,000 | ||||
Common stock, shares issued | 18,408,333 | 18,408,333 | ||||
Common stock, shares outstanding | 18,408,333 | 18,408,333 | ||||
Preferred stock, shares issued | 0 | 0 | ||||
Preferred stock, shares outstanding | 0 | 0 | ||||
Board of Directors Chairman [Member] | Noncontrolling Interest [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Authorized capital stock | 505,000,000 | 505,000,000 | ||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | ||||
Common stock, par value | $ 0.0001 | $ 0.0001 | ||||
Designated shares | 5,000,000 | 5,000,000 | ||||
Net loss attributable to the noncontrolling interest | $ 6,953 | $ 6,953 | ||||
Non-controlling interest percentage | 68% | 68% | ||||
Board Of Directors Chairman One [Member] | Noncontrolling Interest [Member] | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Authorized capital stock | 505,000,000 | 505,000,000 | ||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | ||||
Common stock, par value | $ 0.0001 | $ 0.0001 | ||||
Designated shares | 5,000,000 | 5,000,000 | ||||
Preferred stock, shares issued | 0 | 0 | ||||
Preferred stock, shares outstanding | 0 | 0 | ||||
Net loss attributable to the noncontrolling interest | $ 528,852 | $ 528,852 | ||||
Non-controlling interest percentage | 45% | 45% |
Legal proceedings (Details Narr
Legal proceedings (Details Narrative) | Apr. 12, 2024 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Amount demanded | $ 1,745,366.27 |
Subsequent events (Details Narr
Subsequent events (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
Aug. 13, 2024 | Jul. 12, 2024 | Jul. 09, 2024 | Jul. 08, 2024 | Jul. 01, 2024 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Subsequent Event [Line Items] | ||||||||||
Number of shares issued for convertible notes, value | $ 181,523 | $ 469,260 | $ 319,293 | $ 657,719 | ||||||
Convertible Notes Payable [Member] | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Number of shares issued for convertible notes | 376,836,794 | 389,304,825 | ||||||||
Number of shares issued for convertible notes, value | $ 319,293 | $ 657,719 | ||||||||
Subsequent Event [Member] | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Common stock issued for services, shares | 33,333,333 | 25,000,000 | ||||||||
Common stock issued for services, price per shares | $ 0.0006 | $ 0.0008 | ||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Number of shares issued for convertible notes | 68,181,818 | 76,562,500 | ||||||||
Number of shares issued for convertible notes, value | $ 30,000 | $ 35,000 | ||||||||
Consulting Services [Member] | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Common stock issued for services, shares | 76,000,000 | 115,257,394 | ||||||||
Consulting Services [Member] | Subsequent Event [Member] | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Common stock issued for services, shares | 10,000,000 | 10,000,000 | 2,000,000 | |||||||
Common stock issued for services, price per shares | $ 0.0006 | $ 0.0008 | $ 0.0008 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | 6 Months Ended | ||
Mar. 22, 2023 ft² | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |||
Area of land | ft² | 1,700 | ||
Lease term | 60 months | ||
Lease expiration date | Apr. 30, 2028 | ||
Payment for rent | $ | $ 12,846 | $ 12,604 | |
Weighted average discount rate | 1.10% |